None listed
Conditions
Brief summary
A differential follicular response is observed with the use of HP-hMG, resulting in fewer intermediate-sized follicles. The clinical pregnancy rate obtained with HP-hMG in PCO subjects undergoing ICSI is similar with rFSH.
Interventions
Arm 1: highly purified HMG;
Arm2: recombinant FSH
HP-hMG administered by intramuscular (i.m.) injections, rFSH subcutaneausly,
patients underwent controlled ovarian hyperstimulation following down-regulation with a gnrh agonist in a long protocol. leuprolide acetate, 1mg /days subcutaneausly (lucrine; abbott) was initiated 5-7 days before the estimated start of next menses and continued as 0.5 mg/days until end of gonadotropin administration. gonadotropin administration was initiated when do
Arm 1: highly purified HMG; Arm2: recombinant FSH HP-hMG administered by intramuscular (i.m.) injections, rFSH subcutaneausly, patients underwent controlled ovarian hyperstimulation following down-regulation with a gnrh agonist in a long protocol. leuprolide acetate, 1mg /days subcutaneausly (lucrine; abbott) was initiated 5-7 days before the estimated start of next menses and continued as 0.5 mg/days until end of gonadotropin administration. gonadotropin administration was initiated when down-regulation was confirmed by using transvaginal ultrasound showing no ovarian cysts, and endometrium with a thickness of <5 mm or serum estradiol <50 pg/ml. the starting dose of HP-hMG or rFSH was 150 iu for the first three days, followed by according to the patient’s follicular response. choriongonadotropin alfa, 250 microgram subcutaneausly (ovitrelle; serono), was administered within a day of observing three or more follicles of greather than or equal to18 mm diameter to induce final follicular maturation.
Sponsors
Sertac Batioglu
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
18 Years to 39 Years
Healthy volunteers
No
Inclusion criteria
Group of infertile women aged 18-39 years who manifest sonographic evidence of polycystic ovarian morphology (POM) but who do not have any clinical manifestation of the polycystic ovarian syndrome (PCOS)
Exclusion criteria
early follicular phase serum FSH levels less than or equal to 12 IU/l and abnormal levels of prolactin and partners with semen abnormalities requiring TESE.
Outcome results
None listed